Recent Blog Articles
5 inflammation-fighting food swaps
Is IBD an underrecognized health problem in minority groups?
Sickle cell disease in newborns and children: What families should know and do
COVID-19 vaccines for children and teens: What we do — and don’t — know
Happy trails: Take a hike, now
Sleep well — and reduce your risk of dementia and death
COVID-19 vaccines and the LGBTQ+ community
Polycystic ovary syndrome and the skin
Dental appliances for sleep apnea: Do they work?
Terrified of needles? That can affect your health
Harvard Health Blog
Meningitis vaccines: What parents need to know
- Author: Claire McCarthy, MD,
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Before the introduction of the Menactra and Menveo vaccines in 2005 and 2010 respectively, incidence rate of meningococcal disease in the US was ~1 in 100,000.
The Menveo package insert https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf
“Among subjects with symptom onset within 42 days of vaccination (days 12, 25, 29), 3/12049 [0.02%, 95% CI: (0.01% ,0.07%)] MENVEO recipients and 0/2877 [0%, 95% CI: (0%, 0.13%)] control recipients were diagnosed with Kawasaki Disease.”
This article explains why Kawasaki disease occurs following Menveo.
SIDS, Kawasaki Disease and narcolepsy: Same mechanism, different vaccines.
So we are trading a 1 in 100,000 meningococcal disease rate for a 1 in 4000 Kawasaki disease rate?
Commenting has been closed for this post.